The superparamagnetic nanoparticles of magnetite citrate (SNMCs) consisting of nanospheres aggregates with the hydrodynamic diameter being between 15 to 35 nm with a magnetite core diameter of 3 to 12 nm, coated with of citrate anions was synthesized. A water 25% sol of SNMC was successfully tested as magnetic resonance imaging (MRI) contrast agent. The same 40% sol was then combined with Inox and used at regional magneto-thermo-chemotherapy (RMTCT) of Lewis lung carcinoma (LLC) and Ehrlich carcinoma (EC), in female C57Bl / 6j mice. In the early stages of carcinoma development, the proliferation centers of LLC and EC cells were visualized and, during treatment, they obtained a significant increase in the efficiency of regional magneto-thermo-chemo-therapy.

The water-based magnetite Fe3O4, maghemite gamma-Fe2O3, Gd-substituted ferrites Fe[GdxFe2 (x)] O-4, Ni-Cu alloy particles suspensions and dextran-ferrite (DF) solutions were prepared for the magnetically controlled thermochemotherapy (MCT). The temperature elevation prepared nanoparticles in AC magnetic field (0.88 MHz, 7.3 kA/m, 0.15 kW) and their toxicity were characterised. The results are in a good agreement with physical and chemical properties observed by in vitro measurements. The moment and Curie temperature of magnetic nanoparticles are obtained. The corresponding models of magnetic structure for magnetite, maghemite and Gd-doped ferrites are discussed.

As a result of consecutive intravenous injections of combination from 0.05 up to 1.0 ml 1.0-10 % sol Dextran-ferrite (DF), and 0.001-0.02 ml Magnevist contrast-enhansend (CE) MRI, have reduced to 4 days time of early visualization CE MRI of proliferation centres of glial tumor. Electron-touch mapping DF in a tumor and a liver have defined size of a ratio of contents DF in a tumor to contents DF in a liver ≥ 100 at which combined photodynamic magneto-thermochemotherapy, was preferable and have increased life span of rats with glioma C6 (GC6) up to 166% and at glioblastoma 101/8 (GB 101/8) up to 74%.

Traditional pharmaceutics and therapies do not allow early and reliable diagnosis of malignant tumors and do not guarantee that a therapy optimal for each specific patient is prescribed. Traditional anticancer drugs and therapies fail to ensure full recovery of patients at late oncogenesis stages. Therefore, search for new anticancer drugs and development of their application strategies is in progress. Among recent findings we could mention magnetically controlled therapeutic and diagnostic nanopreparations (MNPs), techniques for tumor visualization and contrast agents for tumor diagnosis, as well as techniques for drug delivery to damaged cells and therapy [1–10].

Citric-ferrite sol (CFS) has been synthesized and successfully tested as MRI negative contrast preparation for revealing primary tumors, and also invasions and metastases at the tumor relapses. Magnetohydrodynamic thermochemotherapy (MTC) by Cysplatin (CP), Mitoxantron (MX), Melphalan (MP) combined with CFS, which were carefully monitoring in vivo and quantified by an electronic detector, improved results of cancer treatment. At various stages of oncogenesis, MTC with CFS at a dose of 62 mg Fe/kg combined with chemotherapeutic drugs was performed at +48º C for 30 min. While such MTC, treatment of ~30 mm3 B 16 melanoma tumor by AC magnetic field led to tumor regression in female mice up to 40 %, and an increase of life span up to 300 % was achieved.

Dextran-ferrite (DF) nanoparticles were synthesized and the related DF sol was successfully tested in vivo as a negative contrast agent for enhancing early magnetic resonance imaging (MRI) detection of tumor, capsule, and tumor-feeding vessels. Intravenous injection of DF in combination with Magnevist and subsequent T2,T 2 * -weighted 3D scanning gave enhanced MRI images that defined the arrangement and functional state of surface and other vessels feeding capsule and tumor in C57Bl/6j mice with a mammary adenocarcinoma (Ac755) model.

Dextran ferrite (DF) nanoparticles were synthesized and related DF sol was successfully tested in vivo as a negative contrast agent enhancing early magnetic resonance tomography (MRT) detection of tumor, capsule, and tumor-feeding vessels. Intravenous introduction of DF in combination with Magnevist and subsequent T2,T2*-weighed 3D scanning gave enhanced MRT images determining the arrangement and functional state of surface and other vessels feeding capsule and tumor in C57Bl/6j mice with model of mammary adenocarcinoma (Ac 755).